UK – NICE approves Ibrance via Cancer Drugs Fund

The National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Ibrance (palbociclib), through the Cancer Drugs Fund (CDF), for use in combination with fulvestrant for the treatment of women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer, who have received prior endocrine therapy.

Pfizer announced that the recommendation is based on data from the Phase III clinical trial, PALOMA-3, in which Ibrance delayed disease progression by 6.6 months, compared to fulvestrant alone.

On the announcement of the news, the drug combination will be available on the NHS immediately, for use in those who have already had earlier rounds hormone therapy for their advanced disease.

Pfizer also revealed an estimation that as many as 3,200 women in England living with advanced HR+, HER2- breast cancer will now be eligible for the treatment…